Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IPH4502

Antibody-drug conjugate · Cytotoxic, directed at nectin-4 · developed by Innate Pharma

Phase 1 Most advanced trial
IPHA Developer
1 Registered trials

What is IPH4502?

IPH4502 is an antibody-drug conjugate in which a humanized IgG1 antibody binds nectin-4 on tumor cells and delivers the topoisomerase I inhibitor exatecan through a cleavable linker. After internalization, released exatecan inhibits DNA replication and induces tumor cell apoptosis, with a bystander effect on neighboring cells. It is being studied in advanced or metastatic solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
nectin-4
Mechanism
Cytotoxic, directed at nectin-4
Pathways
DNA topoisomerase I inhibition, apoptosis, ADCC, CDC, bystander effect
Therapy area
Oncology
Developer
Innate Pharma (IPHA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06781983 Phase 1 Advanced or Metastatic Solid Tumors Active not recruiting IPHA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced or Metastatic Solid Tumors

Other drugs acting on NECTIN4

More from Innate Pharma

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.

Follow IPHA, the company behind IPH4502

See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IPHA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.